Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   IDIX Idenix

BioPharma« Terug naar discussie overzicht

IDIX Idenix

Volgen
17 Posts
| Omlaag ↓
  7. [verwijderd] 15 juni 2009 18:45
    quote:

    spyfly schreef:

    Crack, heb deze ook al langere tijd op mijn watchlist en wil instappen.

    Zit jij hier nog (opnieuw) in?
    zit erg vol in insmed en voorlopig geen plannen die te verkopen

    heb sqnm gekocht voor trade, grote kans terug naar 10$ binnen maand of twee

    IDIX recent nieuws... kan positief of negatief zijn, maar novartis heeft zijn kant van verplichtingen aangepast

    GOede samenvatting van Dew
    Posted by: DewDiligence Date: Wednesday, May 20, 2009 6:08:05 PM
    In reply to: None Post # of 79556

    IDIX is granting NVS a third seat on IDIX’s BoD, which will be increased from 9 to 10 directors. In return for this, NVS has waived its right to participate on a pro rata basis in future IDIX financing transactions and has waived its right to have NVS’ shares of IDIX registered for resale. These agreements became effective yesterday and are reported in an SEC 13D/A filing today:

    sec.gov/Archives/edgar/data/1093649/0...

    What does all this mean? Several things:

    • NVS has retained 100% of its 31,309.498 shares of IDIX common stock. Due to the 2.5M shares IDIX issued to GSK as part of the IDX899 partnership (#msg-37350098), NVS’ equity stake in IDIX declined from 55.6% to 53.0%.

    • NVS does not intend to sell any of its IDIX shares on the open market, even though NVS had the contractual right under the prior agreement between NVS and IDIX to have its shares registered for resale. Under the new agreement, NVS has waived its registration rights, and hence NVS’ shares of IDIX could be sold only as part of a major transaction such as a merger or buyout.

    • Subject to market conditions, IDIX is likely to pursue a financing transaction. IDIX has not yet used any of the $100M shelf registration in Form S-3/A filed on 10/17/08 and could do so as soon as the SEC declared the shelf registration “effective.” (The SEC has not yet done this because IDIX asked the SEC to defer the effective date of the shelf until IDIX files another S-3/A to give the SEC the go-ahead.)

    • By waiving its right to participate on a pro rata basis in any IDIX financing under the shelf registration, NVS is implicitly allowing its equity IDIX stake in IDIX to fall below 50% for the first time since 2003 (when the original partnership deal between the companies was inked).

    • If NVS’ equity stake falls below 50% due to a new IDIX financing, IDIX will for the first time become a buyout candidate for a prospective suitor other than NVS.

    All told, these changes have both bullish and bearish features for IDIX investors . Whether the net result is bullish or bearish is open to debate.

  8. spyfly 15 juni 2009 18:59
    quote:

    crackedtooth schreef:

    [quote=spyfly]
    Crack, heb deze ook al langere tijd op mijn watchlist en wil instappen.

    Zit jij hier nog (opnieuw) in?
    [/quote]

    zit erg vol in insmed en voorlopig geen plannen die te verkopen

    heb sqnm gekocht voor trade, grote kans terug naar 10$ binnen maand of twee

    IDIX recent nieuws... kan positief of negatief zijn, maar novartis heeft zijn kant van verplichtingen aangepast

    GOede samenvatting van Dew
    Posted by: DewDiligence Date: Wednesday, May 20, 2009 6:08:05 PM
    In reply to: None Post # of 79556

    IDIX is granting NVS a third seat on IDIX’s BoD, which will be increased from 9 to 10 directors. In return for this, NVS has waived its right to participate on a pro rata basis in future IDIX financing transactions and has waived its right to have NVS’ shares of IDIX registered for resale. These agreements became effective yesterday and are reported in an SEC 13D/A filing today:

    sec.gov/Archives/edgar/data/1093649/0...

    What does all this mean? Several things:

    • NVS has retained 100% of its 31,309.498 shares of IDIX common stock. Due to the 2.5M shares IDIX issued to GSK as part of the IDX899 partnership (#msg-37350098), NVS’ equity stake in IDIX declined from 55.6% to 53.0%.

    • NVS does not intend to sell any of its IDIX shares on the open market, even though NVS had the contractual right under the prior agreement between NVS and IDIX to have its shares registered for resale. Under the new agreement, NVS has waived its registration rights, and hence NVS’ shares of IDIX could be sold only as part of a major transaction such as a merger or buyout.

    • Subject to market conditions, IDIX is likely to pursue a financing transaction. IDIX has not yet used any of the $100M shelf registration in Form S-3/A filed on 10/17/08 and could do so as soon as the SEC declared the shelf registration “effective.” (The SEC has not yet done this because IDIX asked the SEC to defer the effective date of the shelf until IDIX files another S-3/A to give the SEC the go-ahead.)

    • By waiving its right to participate on a pro rata basis in any IDIX financing under the shelf registration, NVS is implicitly allowing its equity IDIX stake in IDIX to fall below 50% for the first time since 2003 (when the original partnership deal between the companies was inked).

    • If NVS’ equity stake falls below 50% due to a new IDIX financing, IDIX will for the first time become a buyout candidate for a prospective suitor other than NVS.

    All told, these changes have both bullish and bearish features for IDIX investors . Whether the net result is bullish or bearish is open to debate.

    Zit zelf ook vol Insmed...al voor goedkeuring Iplex, dus ben tevreden dat we weer op een betere koers varen.

    Dank voor de info, heb een bescheiden positie ingenomen. Zie nu uptrent, wellicht ben ik er weer snel uit gezien laatste nieuws.
  11. [verwijderd] 26 juni 2009 22:45
    quote:

    spyfly schreef:

    Flinke omzetten ook hier op het eind (en stijgende koers). Omzet van 70k van 408k in enkele minuten (avg volume is 94k).

    @ Crack: thnx nog voor de chart...zit er nog in en wacht rustig af. Zit jij nog in SQNM?

    sqnm : ja, risico, maar hoog return potentieel op korte termijn 1-2mnd
  14. spyfly 21 juli 2009 18:16
    Idenix shares fall following 2Q report, study data
    (AP) – 14 minutes ago
    NEW YORK — Shares of Idenix Pharmaceuticals Inc. plunged Tuesday after the biotechnology company reported a wider-than-expected second-quarter loss and one analyst said financing issues could weaken its position in partnership discussions.
    The stock shed $1.19, or 23.9 percent, to reach $3.80 in afternoon trading. Shares have traded between $1.86 and $10.10 over the past 52 weeks.
    Late Monday, the Cambridge, Mass.-based company said it lost 28 cents per share during the quarter, wider than Wall Street's forecast of 25 cents per share. Revenue of $2.4 million also fell short of analysts' $3.4 million forecast.
    The company receives its revenue through partnerships. Its lead hepatitis C drug candidate IDX-184 recently passed a midstage "proof-of-concept" study. Positive results from the three-day study will prompt the company to move the drug into later stages of development and several analysts believe that Novartis AG will exercise a partnership option on the experimental drug by the end of the year.
    JMP Securities analyst Liisa Bayko, though, downgraded shares to "Market Perform" from "Market Overweight" Tuesday, citing the company's financing position. The company had $51.7 million in cash, cash equivalents and marketable securities as of June 30 and said it expects to have funding for operations through at least the first quarter of 2010.
    Bayko said she had hoped to see more of an antiviral effect in the recent study, but the results indicate a greater effect at higher doses. That could lead to Novartis exercising their option on the drug by year end, she added.
    "However, with cash sufficient only until the first quarter of 2010, we believe Idenix could be in a weak position going into negotiations with Novartis and will likely need to engage in a dilutive financing in the near term to bolster its position," she said in a note to investors.
    Meanwhile, Caris & Co. analyst David Moskowitz reaffirmed a "Buy" rating on the stock and expects shares to reach $16 over the next 52 weeks. He said IDX-184's safety profile and better potency than a prior drug candidate will prompt Novartis to opt into the drug's development. That could result in an upfront payment of $25 million, he said, along with development funding.

    www.google.com/hostednews/ap/article/...

  17. [verwijderd] 9 januari 2012 15:22
    Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) is up 43.97% in pre market trading at $10.10. IDIX has traded 44 thousand shares so far today and trades 910 thousand shares a day on average. IDIX is up today after the company gave an update on its HCV development pipeline. News of Bristol-Myers buyout of Inhibitex has also sent the stock higher. The company has a market cap of 677.88 million.

    www.prnewswire.com/news-releases/iden...

    Idenix Pharmaceuticals, Inc.
    (Public, NASDAQ:IDIX) Pre-market: 9.85 +2.80 (+39.72%)

    Skip
17 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
AZERION 1,210 +0,06 +5,22%
EBUSCO HOLDING 0,910 +0,04 +4,83%
Brunel 8,660 +0,31 +3,71%
PostNL 1,042 +0,03 +3,17%
Pharming 0,725 +0,02 +2,77%
Galapagos 26,460 +0,62 +2,40%
THEON INTERNAT 10,420 +0,20 +1,96%
CTP 15,160 +0,28 +1,88%
HEIJMANS KON 28,000 +0,50 +1,82%
OCI 11,240 +0,20 +1,77%
Sif Holding 12,140 +0,18 +1,51%
Eurocommercial Properties 23,500 +0,30 +1,29%
FASTNED 21,400 +0,25 +1,18%
ACOMO 17,480 +0,20 +1,16%
Alfen N.V. 11,680 +0,13 +1,13%
Aperam 26,980 +0,28 +1,05%
NSI 19,700 +0,20 +1,03%
JDE PEET'S 18,950 +0,19 +1,01%
Wereldhave 14,000 +0,14 +1,01%
UNILEVER PLC 56,740 +0,56 +1,00%
Ahold Delhaize 32,850 +0,32 +0,98%
RANDSTAD NV 41,390 +0,39 +0,95%
ALLFUNDS GROUP 5,370 +0,05 +0,94%
NX FILTRATION 4,100 +0,03 +0,86%
KPN 3,669 +0,03 +0,77%
ASCX 1.174,63 +8,58 +0,74%
ArcelorMittal 23,150 +0,16 +0,70%
Flow Traders 21,160 +0,14 +0,67%
UMG 22,640 +0,14 +0,62%
WDP 20,680 +0,12 +0,58%
Akzo Nobel 55,340 +0,32 +0,58%
Heineken 70,120 +0,40 +0,57%
INPOST 17,560 +0,10 +0,57%
Van Lanschot Kempen NV 42,200 +0,20 +0,48%
Aegon 5,916 +0,03 +0,44%
AALBERTS NV 34,040 +0,14 +0,41%
Nedap N.V. 52,800 +0,20 +0,38%
Corbion 21,800 +0,08 +0,37%
IMCD 139,950 +0,50 +0,36%
Fagron 18,620 +0,06 +0,32%
Wolters Kluwer 157,700 +0,35 +0,22%
ING 14,466 +0,03 +0,19%
RELX 44,620 +0,06 +0,13%
PROSUS 38,050 +0,04 +0,11%
AMX 862,54 +0,85 +0,10%
TKH 30,880 +0,02 +0,06%
ADYEN NV 1.385,400 +0,20 +0,01%
Vastned 24,400 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
AMG Critical Materials N.V. 14,290 -0,50 -3,38%
Air France-KLM 7,258 -0,23 -3,05%
JUST EAT TAKEAWAY 14,490 -0,36 -2,42%
BESI 108,450 -2,45 -2,21%
CM.COM 5,840 -0,13 -2,18%
ASML 627,700 -12,30 -1,92%
ASMI 494,900 -8,30 -1,65%
Accsys 0,577 -0,01 -1,54%
Avantium 2,105 -0,03 -1,41%
B&S Group SA 4,310 -0,06 -1,37%
RENEWI 6,700 -0,09 -1,33%
Basic-Fit 21,060 -0,26 -1,22%
Kendrion 10,620 -0,12 -1,12%
SIGNIFY NV 20,820 -0,18 -0,86%
TomTom 5,210 -0,04 -0,76%
ASR Nederland 44,330 -0,31 -0,69%
Arcadis 61,900 -0,40 -0,64%
ForFarmers 3,220 -0,02 -0,62%
NN Group 43,670 -0,23 -0,52%
SHELL PLC 30,715 -0,16 -0,52%
ABN AMRO BANK N.V. 14,540 -0,06 -0,38%
EXOR NV 93,550 -0,35 -0,37%
DSM FIRMENICH AG 104,550 -0,35 -0,33%
Fugro 16,750 -0,05 -0,30%
Sligro 10,780 -0,02 -0,19%
Vopak 44,080 -0,08 -0,18%
BAM 3,916 0,00 -0,10%
AEX 874,48 -0,66 -0,08%
SBM Offshore 17,120 -0,01 -0,06%
Philips Koninklijke 25,750 -0,01 -0,04%
vlag naam koers verschil relatief verschil
AEX 874,48 -0,66 -0,08%
AEX GR 3.430,00 -2,59 -0,08%
Germany40^ 19.250,20 -45,78 -0,24%
FTSE 100 8.274,75 +16,14 +0,20%
EURO50 4.726,63 -32,29 -0,68%
US30^ 44.776,00 -73,80 -0,16%
Nasd100^ 20.660,20 -263,20 -1,26%
US500^ 5.992,41 -29,75 -0,49%
Japan225^ 37.667,70 -665,50 -1,74%
VD-NEW 15,84 +0,23 +1,45%
#/^ Index indications calculated real time, zie disclaimer